CNS targeted AAV gene therapies: Recent advances and clinical insights.
Gene therapies using modified viruses show promise for rare brain and nervous system diseases, with emerging evidence guiding safer design and delivery.
This authoritative review from CHOP's gene therapy center synthesizes clinical and postmarketing evidence for AAV gene therapies with focus on CNS indications, covering both successes and persistent barriers. It synthesizes practical guidance on capsid engineering, delivery routes, and safety relevant to the expanding rare CNS disease treatment landscape.
What the study was
- Study design
- Comprehensive review synthesizing clinical trial and postmarketing data from AAV gene therapies including 8 FDA-approved therapies (4 CNS indications)
- Population
- Patients with rare neurological disorders addressed by FDA-approved AAV therapies
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Cell Reports Medicine
Why it surfaced
Authoritative synthesis of CNS AAV gene therapy clinical and postmarketing evidence from a leading center; directly relevant to rare neurological diseases with high unmet need.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.